Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) – Investment analysts at Wedbush issued their Q3 2022 earnings per share (EPS) estimates for Gossamer Bio in a note issued to investors on Monday, September 19th. Wedbush analyst A. Argyrides expects that the company will post earnings of ($0.84) per share for the quarter. Wedbush has a "Outperform" rating and a $24.00 price objective on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($2.69) per share. Wedbush also issued estimates for Gossamer Bio's Q4 2022 earnings at ($0.84) EPS, FY2022 earnings at ($3.17) EPS, Q1 2023 earnings at ($0.84) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.86) EPS, Q4 2023 earnings at ($0.86) EPS, FY2023 earnings at ($3.41) EPS, FY2024 earnings at ($3.52) EPS, FY2025 earnings at ($3.64) EPS and FY2026 earnings at ($2.97) EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Gossamer Bio in a research note on Thursday, July 14th. Raymond James boosted their price target on Gossamer Bio from $10.00 to $14.00 and gave the stock an "outperform" rating in a research note on Thursday, July 14th. Finally, Barclays boosted their price target on Gossamer Bio from $12.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 17th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Gossamer Bio currently has a consensus rating of "Buy" and a consensus price target of $19.33.

Gossamer Bio Trading Up 0.6 %

Gossamer Bio (NASDAQ:GOSS – Get Rating) last released its earnings results on Tuesday, August 9th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.07).

Institutional Trading of Gossamer Bio

Several hedge funds have recently bought and sold shares of GOSS. Point72 Hong Kong Ltd bought a new stake in Gossamer Bio during the first quarter valued at about $33,000. Amalgamated Bank bought a new stake in Gossamer Bio during the first quarter valued at about $65,000. Denali Advisors LLC bought a new stake in Gossamer Bio during the second quarter valued at about $75,000. Teacher Retirement System of Texas bought a new stake in Gossamer Bio during the first quarter valued at about $89,000. Finally, Corton Capital Inc. bought a new stake in Gossamer Bio during the second quarter valued at about $91,000. Institutional investors own 67.57% of the company's stock.

Insider Activity at Gossamer Bio

In other news, CEO Faheem Hasnain acquired 138,696 shares of Gossamer Bio stock in a transaction that occurred on Friday, July 15th. The stock was bought at an average price of $7.21 per share, for a total transaction of $999,998.16. Following the completion of the transaction, the chief executive officer now owns 3,617,325 shares in the company, valued at $26,080,913.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Faheem Hasnain acquired 138,696 shares of Gossamer Bio stock in a transaction that occurred on Friday, July 15th. The stock was bought at an average price of $7.21 per share, for a total transaction of $999,998.16. Following the completion of the transaction, the chief executive officer now owns 3,617,325 shares in the company, valued at $26,080,913.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Laura Carter sold 8,808 shares of the company's stock in a transaction on Friday, July 1st. The shares were sold at an average price of $8.25, for a total value of $72,666.00. Following the sale, the insider now owns 80,234 shares of the company's stock, valued at approximately $661,930.50. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 159,499 shares of company stock worth $1,149,988. 8.30% of the stock is owned by insiders.

About Gossamer Bio

(Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Stories

• Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Is Ford Rolling To A Rebound After Its Q3 Warning
• Has AMD stock stock fallen too far?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.